FDAnews Drug Daily Bulletin

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

Aug. 12, 2014
A A

Mirati Therapeutics announced that the FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL).
Yahoo Finance